Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
As lobbyists purporting to represent doctors and hospitals fight attempts to control surprise medical bills, it has become increasingly clear that the force behind the effort is not just medical professionals, but also investors from private equity firms.
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
The Wednesday night event marked the second night in a row for Democratic presidential hopefuls to stake claims on how to fix the health care system.
Hay casi tantas versiones de “Medicare para Todos” como candidatos demócratas, y cada uno piensa que su plan es el camino para asegurar a todos los estadounidenses.
Candidates used their varying views on how to achieve universal coverage — whether through Medicare for All or more incremental steps — as a means to differentiate themselves from the field.
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Despite what New York Mayor Bill de Blasio claimed during the first night of the presidential debates, universal health care in the Big Apple is still in the seeding stage.
Supporters of the rule say it would strengthen health care professionals’ freedom of conscience, but opponents say it “empowers bad actors to be bad actors.”
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
It’s as shady as it sounds.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
Key House and Senate committees kick off hearings on drug prices, and patients’ families weigh in with tragic stories.
Patients and doctors got a chance to share their nightmarish experiences with medical bills with President Donald Trump and other top White House officials.
Top House Republican also received more than $1 million from drugmakers since 2007.